Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
D Zhao, B Zhai, C He, G Tan, X Jiang, S Pan, X Dong… - Cellular signalling, 2014 - Elsevier
Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
D Zhao, B Zhai, C He, G Tan, X Jiang, S Pan, X Dong… - Cellular …, 2014 - infona.pl
Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
[引用][C] Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
D Zhao, B Zhai, C He, G Tan, X Jiang, S Pan… - Cellular …, 2014 - cir.nii.ac.jp
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the
TGF-α/EGFR pathway in hepatocellular carcinoma cells | CiNii Research CiNii 国立情報学 …
TGF-α/EGFR pathway in hepatocellular carcinoma cells | CiNii Research CiNii 国立情報学 …
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells.
D Zhao, B Zhai, C He, G Tan, X Jiang, S Pan… - Cellular …, 2014 - europepmc.org
Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
Upregulation of HIF-2α induced by sorafenib contributes to the resistance by activating the TGF-α/EGFR pathway in hepatocellular carcinoma cells
D Zhao, B Zhai, C He, G Tan, X Jiang… - Cellular …, 2014 - pubmed.ncbi.nlm.nih.gov
Sorafenib, the first-line systemic drug for advanced hepatocellular carcinoma (HCC), has
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …
demonstrated limited benefits with very low response rates. Thus it is essential to investigate …